Ignite Creation Date:
2024-10-26 @ 3:42 PM
Last Modification Date:
2024-10-26 @ 3:42 PM
Study NCT ID:
NCT06640010
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-10-11
Brief Title:
Using Induced-Pluripotent Stem Cells to Model Cancer Therapy-Related Adverse Events
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Using Induced-Pluripotent Stem Cells to Model Cancer Therapy-Related Adverse Events
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is being done to find out if patient blood samples can be used to perform individualized modeling of cancer therapy-related side effects
Detailed Description:
PRIMARY OBJECTIVES
I Generate induced pluripotent stem cells iPSCs from patients receiving cancer treatment
II Differentiate patient iPSCs into cardiomyocytes andor neurons or other cell types that may be relevant to modeling cancer therapy-related adverse effects such as cardiotoxicity and neurotoxicity
III Use patient specific iPSC-derived cells to
IIIa Model cancer therapy-related toxicities IIIb Better understand the mechanisms of toxicities IIIc Determine if patient specific genetic variants are causative of toxicities IIId Screen novel protective therapies for cancer therapy-related toxicities
OUTLINE This is an observational study
Patients undergo blood sample collection and have their medical records reviewed on study
I Generate induced pluripotent stem cells iPSCs from patients receiving cancer treatment
II Differentiate patient iPSCs into cardiomyocytes andor neurons or other cell types that may be relevant to modeling cancer therapy-related adverse effects such as cardiotoxicity and neurotoxicity
III Use patient specific iPSC-derived cells to
IIIa Model cancer therapy-related toxicities IIIb Better understand the mechanisms of toxicities IIIc Determine if patient specific genetic variants are causative of toxicities IIId Screen novel protective therapies for cancer therapy-related toxicities
OUTLINE This is an observational study
Patients undergo blood sample collection and have their medical records reviewed on study
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None